A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria
Status:
Not yet recruiting
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to assess the efficacy and safety or a revised weight band
tafenoquine dose in vivax malaria patients. The main question[s] it aims to answer are:
- is a revised weight-based TQ regimen (TQRevised: target dose 7.5mg/kg) non-inferior to
high dose primaquine (7mg/kg over 7 days)
- is a revised weight-based TQ regimen (TQRevised: target dose 7.5mg/kg) superior to fixed
dose tafenoquine (300mg)
- is the tolerability and safety of TQRevised acceptable
- is TQRevised acceptable and feasible Participants will receive a tafenoquine target dose
7.5mg/kg in weight bands. Researchers will compare this to patients receiving a fixed
dose tafenoquine and high dose primaquine to see if safe and effective.
Phase:
Phase 3
Details
Lead Sponsor:
Menzies School of Health Research
Collaborators:
Addis Ababa University Arba Minch University Curtin University Eijkman Research Center for Molecular Biology, National Research and Innovation Agency, Indonesia Fundação de Medicina Tropical Dr. Heitor Vieira Dourado Papua New Guinea Institute of Medical Research Papuan Community Health and Development Foundation, Indonesia University of Melbourne